Adenovirus-mediated transfer of genes to the lung
AssigneeTransgene S.A.
InventorsRonald G. Crystal, Wilfried Dalemans, Michel Perricaudet, Leslie Stratford-Perricaudet, Andrea Pavirani
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.
Claims14
A method of producing a biologically active protein in a lung of an animal, comprising:
- administering to the lung of said animal a replication deficient adenovirus comprising a DNA segment encoding said protein and under conditions such that said DNA segment is expressed and said protein thereby produced.
A method of treating cystic fibrosis in a patient comprising:
- administering to the lung of said patient a replication deficient adenovirus comprising a DNA segment encoding a cystic fibrosis transmembrane conductance regulator and under conditions such that said DNA segment is expressed and said regulator thereby produced.
A method of treating α1-antitrypsin deficiency in a patient comprising:
- administering to the lung of said patient a replication deficient adenovirus comprising a DNA segment encoding α1-antitrypsin and under conditions such that said DNA segment is expressed and said α1-antitrypsin thereby produced.
A pharmaceutical composition comprising:
- A replication deficient adenoviral construct comprising at least one DNA segment encoding for a therapeutic protein and
- a pharmaceutically acceptable diluent, carrier, or excipient.
A pharmaceutical composition comprising:
- a replication deficient adenovirus construct comprising a DNA segment encoding a cystic fibrosis transmembrane conductance regulator and
- a pharmaceutically acceptable diluent, carrier, or excipient.
A pharmaceutical composition comprising:
- a replication deficient adenovirus construct comprising a DNA segment encoding α1-antitrypsin and
- a pharmaceutically acceptable diluent, carrier, or excipient.
Dependencies are inferred from the claim text.